Neurocrine Biosciences | NBIX - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
AbbVie USD -5.94B 721M 2026-06
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Cytokinetics USD -173.49M 653.08M 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Exelixis USD 1.84B 91.99M 2026-06
Gilead Sciences USD 11.74B 11.77B 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Incyte USD 6.34B 721.58M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Prothena USD 286.89M 25.72M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Repligen USD 2.11B 6.57M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
Teva Pharmaceutical Industries USD 7.75B 475M 2026-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06